{
  "source": "PA-Notification-Joenja.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1413-3\nProgram Prior Authorization/Notification\nMedication Joenja® (leniolisib)\nP&T Approval Date 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nJoenja (leniolisib) is a kinase inhibitor indicated for the treatment activated phosphoinositide 3-\nkinase delta (PI3Kẟ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Joenja will be approved based upon both of the following criteria:\na. Diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS)\n-AND-\nb. Patient is 12 years of age or older\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Joenja will be approved based on the following criterion:\na. Documentation of positive clinical response to Joenja therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. Reference:\n1. Joenja [package insert]. Foster City, CA: Pharming Technologies, Inc.; March 2023.\nProgram Prior Authorization/Notification - Joenja (leniolisib)\nChange Control\n5/2023 New program\n5/2024 Annual review. Updated initial authorization duration to 12 months.\n5/2025 Annual review with no changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}